文献速递中毒与环境急症消化、代谢与肾脏急症

治疗剂量以上对乙酰氨基酚速释与缓释制剂及其主要代谢物的群体药代动力学研究

Population pharmacokinetics of immediate-release and modified-release paracetamol and its major metabolites in a supratherapeutic dosing study.
PubMed 文献 · Clin Toxicol (Phila) · 2021-06-03
一句话结论基于150 mg/L列线图评估缓释对乙酰氨基酚过量中毒不适用,因两种剂型在相同剂量下列线图评估差异概率可达14.6%。

本研究基于9名健康志愿者单次口服超治疗剂量80 mg/kg速释或缓释对乙酰氨基酚的交叉设计数据,建立群体药代动力学模型描述原药及葡萄糖醛酸结合物(APAPG)、硫酸结合物(APAPS)的浓度时程。缓释制剂相对生物利用度为0.81,其吸收用串联零级后一级并行吸收模型描述。模拟显示基于150 mg/L列线图的毒性评估在速释与缓释制剂间差异概率随剂量增加,摄入22 g后高达14.6%,提示缓释过量不宜用该列线图评估。

要点

  • 缓释对乙酰氨基酚相对速释制剂的生物利用度(FMR/IR)估计为0.81。
  • 基于150 mg/L列线图评估毒性时,速释与缓释制剂间评估差异概率随剂量增加,摄入22 g后高达14.6%。
  • 缓释制剂的延迟时程最佳由并行吸收模型描述,其中缓释组分为串联零级后一级过程。
  • APAPG formation为线性过程,APAPS浓度最佳拟合为Michaelis-Menten过程。
  • 模拟显示基于150 mg/L列线图的毒性评估不适用于缓释对乙酰氨基酚过量。

适用人群与场景

  • 9名健康志愿者,单次口服超治疗剂量80 mg/kg速释或缓释对乙酰氨基酚的交叉设计研究。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为交叉设计药代动力学研究,样本量9名健康志愿者,单中心(原文未明确中心数)。
  • 干预为单次口服80 mg/kg速释或缓释对乙酰氨基酚,比较两者药代动力学及基于150 mg/L列线图的毒性评估差异。
  • 缓释相对速释生物利用度估计为0.81;模拟显示基于150 mg/L列线图评估差异概率随剂量增加,22 g后高达14.6%。
  • 缓释制剂吸收用并行吸收模型(串联零级后一级)描述;APAPG形成为线性,APAPS为Michaelis-Menten过程。

证据类型、等级与局限

  • 证据类型为健康志愿者药代动力学交叉研究;局限包括样本量小(9人)、单次给药、健康人群,非过量患者。原文未给出证据等级或推荐强度。

对床旁实践的改变

  • 提示急诊/ICU在处理缓释对乙酰氨基酚过量时,不应仅依赖150 mg/L列线图评估毒性风险,需考虑剂型差异;该结论基于健康志愿者模拟,需在过量患者中进一步验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Overdose with paracetamol modified-release (MR) formulation, a bilayer tablet containing 69% slow-release component, has been increasing since its introduction to the market. However, little evidence exists for the management of MR paracetamol overdose. We aimed to develop a population pharmacokinetic (PK) model for immediate-release (IR) and MR paracetamol and its major metabolism, and quantitatively understand the formulation difference in toxicity assessment based on the nomogram line.

METHODS: Data from a cross-over study design in nine healthy volunteers administered a single supratherapeutic oral dose (80 mg/kg) of either IR and MR paracetamol were available from a published study. Plasma concentrations for paracetamol and its metabolites glucuronide (APAPG) and sulfate conjugate (APAPS) for both formulations were measured and analysed with population pharmacokinetic (PK) method using NONMEM. Toxicity in both formulations was assessed by comparing the simulated paracetamol concentrations under different paracetamol dose levels with the 150 mg/L nomograms. The difference in the assessment was compared between the two formulations.

RESULTS: Paracetamol concentrations for the IR formulation were described with a two-compartment model with first-order input and a lag time. The delayed time-course of MR paracetamol concentrations was best captured by a parallel absorption model in which the slow-release component was a serial zero-order then the first-order process. The formation of APAPG was linear, while APAPS concentrations were best fitted by a Michaelis-Menten process. The relative bioavailability of MR paracetamol compared to IR (FMR/IR) was estimated as 0.81. The simulated probability of making different toxicity assessments based on nomogram line was increased with dose levels and was as high as 14.6% after 22 g IR or MR paracetamol ingested.

CONCLUSIONS: A joint parent-metabolite model to describe time-course profiles of both IR and MR paracetamol and its metabolites APAPG and APAPS concentrations was developed. Simulations from the model showed that toxicity assessment based on the 150 mg/L nomograms is not suitable in MR paracetamol overdoses.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Li J, Chiew AL, Isbister GK, et al. Population pharmacokinetics of immediate-release and modified-release paracetamol and its major metabolites in a supratherapeutic dosing study. Clin Toxicol (Phila). 2021. PMID: 34080498. doi:10.1080/15563650.2021.1928163

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。